Background: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin Lymphoma worldwide. Rituximab, cyclophosphamide, hydroxydaunorubicin, vincristine and prednisone (R-CHOP) are the current standard therapy. About 10% cases of DLBCL were refractory to these immunochemotherapy and may have poor prognosis. Latest studies showed that C-X-C chemokine receptor type 4 (CXCR4) and Programmed Death Ligand 1 (PD-L1) were involved in DLBCL biology and correlated with patients’ poor survival. This study aimed to investigate the expression of CXCR4 and PD-L1 with clinical characteristics and its response to R-CHOP in DLBCL and their potential benefit as future predictive biomarkers.
Methods: Thirty four cases of newly diagnosed DLBCL were selected from Hasan Sadikin General Hospital, Bandung, Indonesia, during 2015-2018. Treatment outcome was retrieved from patients’ medical records. The expression of CXCR4 and PD-L1 in patients’ tumor tissues were detected using immunohistochemistry.
Results: Five of 34 cases (14.70%) showed poor clinical response to R-CHOP. High CXCR4 expression was detected in 11 of 34 cases (32.35%), it was significantly correlated with clinical stage (p = 0.0003) and poor clinical response (p = 0.029). High PD-L1 expression was detected in 10 of 34 cases (29.41%) and was significantly correlated with patients’ gender (p = 0.022) but was not correlated with poor clinical response (p = 0.138).
Conclusions: CXCR4 in DLBCL increased probability of poor clinical response to R-CHOP, but not PD-L1 expression. This finding provides the ground for further research which relates to CXCR4 as a future predictive biomarker for this challenging malignancy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.